Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Equity Average: 2013-2024

Historic Equity Average for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $685.9 million.

  • Amphastar Pharmaceuticals' Equity Average rose 6.47% to $767.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $767.1 million, marking a year-over-year increase of 6.47%. This contributed to the annual value of $685.9 million for FY2024, which is 17.43% up from last year.
  • Amphastar Pharmaceuticals' Equity Average amounted to $685.9 million in FY2024, which was up 17.43% from $584.0 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Equity Average peaked at $685.9 million during FY2024, and registered a low of $438.1 million during FY2020.
  • In the last 3 years, Amphastar Pharmaceuticals' Equity Average had a median value of $584.0 million in 2023 and averaged $585.7 million.
  • Data for Amphastar Pharmaceuticals' Equity Average shows a peak YoY increased of 19.90% (in 2023) over the last 5 years.
  • Over the past 5 years, Amphastar Pharmaceuticals' Equity Average (Yearly) stood at $438.1 million in 2020, then grew by 2.05% to $447.1 million in 2021, then grew by 8.94% to $487.1 million in 2022, then climbed by 19.90% to $584.0 million in 2023, then rose by 17.43% to $685.9 million in 2024.